GenIbet master’s development and manufacturing of Biopharmaceuticals, including Cell and Gene Therapy products, Recombinant proteins, RNA, Live Microbial Products and Vaccines. Biological banks of mammalian and insect cells, bacteria, yeasts and virus are also be provided.
The GenIbet team has been a strong collaborator for Seres, and has performed very well for us. We are confident in the future of our relationship, and we look forward to continuing to work together for many years to come.
As we enter the New Year, I’m writing to express Seres’ sincere appreciation for the partnership we have enjoyed with GenIbet over the past few years in the development and GMP manufacture of what we expect to be the “first in class” commercialized microbiome therapeutic, SER-109, for the treatment of C. difficile, as well as our clinical candidate SER-287 for the treatment of ulcerative colitis.
Moderna is very thankful to GenIbet Biopharmaceuticals. They partnered together to take the very first Moderna mRNA vaccine in the clinic at the end of 2015. The GenIbet team provided moderna with a high quality GMP product and we are thankful for its work.